Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024;11(1):1-6.
doi: 10.14283/jpad.2023.88.

The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants

C M Erickson  1 , N A Chin, F B Ketchum, M L Eveler, C E Conway, D M Coughlin, L R Clark
Affiliations
Observational Study

The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants

C M Erickson et al. J Prev Alzheimers Dis. 2024.

Abstract

Disclosing Alzheimer's disease (AD) biomarkers to research participants is a growing practice. Here, we aim to synthesize the experiences of clinicians leading preclinical AD biomarker disclosure. Semi-structured interviews were conducted individually with each of the four clinicians conducting biomarker disclosure as a part of a longitudinal, observational AD cohort study. Study clinicians emphasized the importance of participant education, having adequate time available for the disclosure visit, and forms to facilitate disclosure. To train and support future clinicians conducting AD biomarker disclosure, our study clinicians highlighted providing information about AD and biomarkers, shadowing a disclosure visit, having team debriefing sessions, and collating a frequently asked questions document. To date, this is the first characterization of clinician reflections on disclosing AD biomarker result to cognitively unimpaired research participants. As more clinicians in research or clinical settings seek to disclose AD biomarker results, best practices for training clinicians to lead disclosure are necessary.

Keywords: Biomarker disclosure; disclosure practices; research clinician experiences.

PubMed Disclaimer

Conflict of interest statement

CME, NAC, FBK, MLE, CEC, DMC, LRC have no relevant conflicts of interest to disclose.

References

    1. Aducanumab (marketed as Aduhelm) Information. FDA Press Announcements. Published December 1, 2022. Accessed January 17, 2023. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-an...
    1. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment. FDA. Published January 6, 2023. Accessed January 10, 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerat...
    1. Erickson CM, Clark LR, Ketchum FB, Chin NA, Gleason CE, Largent EA. Implications of preclinical Alzheimer’s disease biomarker disclosure for US policy and society. Alzheimers Dement Amst Neth. 2022;14(1):e12339. doi:10.1002/dad2.12339 - DOI - PMC - PubMed
    1. Erickson CM, Chin NA, Johnson SC, Gleason CE, Clark LR. Disclosure of preclinical Alzheimer’s disease biomarker results in research and clinical settings: Why, how, and what we still need to know. Alzheimers Dement Diagn Assess Dis Monit. 2021;13(1):e12150. doi:10.1002/dad2.12150 - DOI - PMC - PubMed
    1. Largent EA, Harkins K, Dyck CH van, Hachey S, Sankar P, Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLOS ONE. 2020;15(2):e0229137. doi:10.1371/journal.pone.0229137 - DOI - PMC - PubMed

Publication types